日本23价肺炎球菌多糖疫苗接种后免疫性血小板减少性紫癜与吉兰-巴雷综合征:疫苗有效性、网络与通用安全性(VENUS)研究
日本于2021年启动VENUS试点系统,利用医保理赔与接种记录数据,采用自身对照病例系列设计评估PPSV23接种后ITP和GBS发生率。ITP在28天和42天风险期的发生率比分别为0.89(95%CI 0.12-6.4)和0.58(95%CI 0.081-4.2),均无统计学显著性;GBS因样本量有限无法估计发生率比。结论认为VENUS研究可为建立先进的疫苗监测系统提供有价值的信息。
要点
- PPSV23接种后28天风险期ITP发生率比为0.89(95%CI 0.12-6.4),无统计学显著性。
- PPSV23接种后42天风险期ITP发生率比为0.58(95%CI 0.081-4.2),无统计学显著性。
- GBS因样本量有限,无法估计发生率比。
核心结论
- VENUS研究可为促进日本建立先进的疫苗监测系统提供有价值的信息。
研究设计与样本
- VENUS研究于2021年作为试点系统启动,利用现有医保理赔数据和接种记录。
- 本研究采用自身对照病例系列设计,评估PPSV23接种后ITP和GBS的发生率。
主要发现
- ITP在28天风险期的发生率比为0.89(95%CI 0.12-6.4),无统计学显著性。
- ITP在42天风险期的发生率比为0.58(95%CI 0.081-4.2),无统计学显著性。
- GBS因样本量有限,无法估计发生率比。
临床怎么用
- 原文未据此给出推荐。
局限性
- GBS因样本量有限,无法估计发生率比。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To address the lack of an active vaccine safety surveillance system in Japan, the Vaccine Effectiveness, Networking, and Universal Safety (VENUS) study was initiated in 2021 as a pilot system using existing health insurance claims data and vaccination records. METHODS: This study evaluated the value of the VENUS study by assessing the incidence of immune thrombocytopenic purpura (ITP) and Guillain-Barré syndrome (GBS) following vaccination with the 23-valent pneumococcal polysaccharide vaccine (PPSV23) using a self-controlled case series (SCCS) design. RESULTS: Incidence rate ratios for ITP during 28-day and 42-day risk periods were 0.89 (95% confidence interval [CI], 0.12-6.4), and 0.58 (95% CI, 0.081-4.2), respectively. Neither was statistically significant. Incidence rate ratios could not be estimated for GBS due to the limited sample size. CONCLUSION: The VENUS study can provide valuable insights to facilitate the establishment of an advanced vaccine monitoring system in Japan.
引用
- Sato S, Katsuta T, Kawazoe Y, et al. Immune thrombocytopenic purpura and Guillain-Barré syndrome after 23-valent pneumococcal polysaccharide vaccination in Japan: The vaccine effectiveness, networking, and universal safety (VENUS) study. Vaccine. 2023. PMID: 38044244. doi:10.1016/j.vaccine.2023.11.053
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。